Ingemar Turesson
Overview
Explore the profile of Ingemar Turesson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
4179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larfors G, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, et al.
Ann Hematol
. 2025 Jan;
104(1):565-572.
PMID: 39849162
Despite advancements in multiple myeloma treatment, prognostic variability persists. We investigated the impact of income and education on treatment and survival in a country with publicly funded healthcare. We analysed...
2.
Blimark C, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, et al.
Haematologica
. 2024 Jul;
110(1):163-172.
PMID: 39021214
In multiple myeloma (MM), advancements in treatments and toxicity management have enhanced survival rates. This, coupled with shifting age demographics in MM, necessitates an updated assessment of infection risks in...
3.
Einarsdottir S, Sverrisdottir I, Villegas-Scivetti M, Day C, Turesson I, Juliusson G, et al.
Haematologica
. 2024 Jun;
110(1):179-182.
PMID: 38934063
No abstract available.
4.
Rognvaldsson S, Thorsteinsdottir S, Syriopoulou E, Sverrisdottir I, Turesson I, Eythorsson E, et al.
Haematologica
. 2024 Jan;
109(7):2250-2255.
PMID: 38205512
There is some evidence that a prior cancer is a risk factor for the development of multiple myeloma (MM). If this is true, prior cancer should be associated with a...
5.
Abildgaard N, Freilich J, Anttila P, Bent-Ennakhil N, Ma Y, Lassenius M, et al.
Clin Epidemiol
. 2023 Sep;
15:987-999.
PMID: 37745645
Purpose: Linked health-care registries and high coverage in Nordic countries lend themselves well to epidemiologic research. Given its relatively high incidence in Western Europe, complexity in diagnosis, and challenges in...
6.
Moore K, Turesson I, Genell A, Klausen T, Knut-Bojanowska D, Redder L, et al.
Haematologica
. 2022 Oct;
108(6):1640-1651.
PMID: 36300775
The prevalence of multiple myeloma (MM) is increasing in Nordic countries and the rest of the western world. Patients aged ≥75 years at diagnosis constitute an increasing proportion of all...
7.
Walinder G, Genell A, Juliusson G, Svensson R, Santamaria A, Crafoord J, et al.
Cancer Rep (Hoboken)
. 2022 Mar;
5(11):e1614.
PMID: 35243814
Background: We wanted to evaluate if health care for multiple myeloma (MM) patients is equal in different regions of Sweden. Aim: To study differences in survival for MM depending on...
8.
Duran-Lozano L, Thorleifsson G, Lopez de Lapuente Portilla A, Niroula A, Went M, Thodberg M, et al.
Blood Cancer J
. 2021 Nov;
11(11):181.
PMID: 34782614
No abstract available.
9.
Blimark C, Juul Vangsted A, Klausen T, Gregersen H, Szabo A, Hermansen E, et al.
Eur J Haematol
. 2021 Sep;
108(2):99-108.
PMID: 34514635
Objective: We describe real-world evidence (RWE) from the nationwide Swedish and Danish registries that provide important information on incidence and outcome in multiple myeloma (MM). Method: First line treatment data...
10.
Shah U, Rognvaldsson S, Derkach A, Bjorkholm M, Turesson I, David Y, et al.
Haematologica
. 2021 Sep;
107(1):284-286.
PMID: 34474548
No abstract available.